161 related articles for article (PubMed ID: 35431567)
1. Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort.
Kendrick JB; Zhou M; Ficociello LH; Parameswaran V; Mullon C; Anger MS; Coyne DW
Int J Nephrol Renovasc Dis; 2022; 15():139-149. PubMed ID: 35431567
[TBL] [Abstract][Full Text] [Related]
2. The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Ramos R; Chazot C; Ferreira A; Di Benedetto A; Gurevich K; Feuersenger A; Wolf M; Arens HJ; Walpen S; Stuard S
BMC Nephrol; 2020 Dec; 21(1):530. PubMed ID: 33287733
[TBL] [Abstract][Full Text] [Related]
3. One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Kendrick J; Parameswaran V; Ficociello LH; Ofsthun NJ; Davis S; Mullon C; Kossmann RJ; Kalantar-Zadeh K
J Ren Nutr; 2019 Sep; 29(5):428-437. PubMed ID: 30679076
[TBL] [Abstract][Full Text] [Related]
4. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
[TBL] [Abstract][Full Text] [Related]
5. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
Kalantar-Zadeh K; Ficociello LH; Zhou M; Anger MS
BMC Nephrol; 2024 Jun; 25(1):197. PubMed ID: 38886636
[TBL] [Abstract][Full Text] [Related]
6. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study.
Coyne DW; Ficociello LH; Parameswaran V; Rosen MM; Mullon C; Kossmann RJ; Sprague SM
Kidney Med; 2020; 2(3):307-316. PubMed ID: 32734250
[TBL] [Abstract][Full Text] [Related]
7. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.
Medaura JA; Zhou M; Ficociello LH; Anger MS; Sprague SM
Am J Nephrol; 2024; 55(2):127-135. PubMed ID: 38091973
[TBL] [Abstract][Full Text] [Related]
8. A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.
Rhee CM; Zhou M; Woznick R; Mullon C; Anger MS; Ficociello LH
Int Urol Nephrol; 2023 Feb; 55(2):377-387. PubMed ID: 35953565
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.
Kalantar-Zadeh K; Ficociello LH; Parameswaran V; Athienites NV; Mullon C; Kossmann RJ; Coyne DW
BMC Nephrol; 2019 Oct; 20(1):396. PubMed ID: 31664928
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide.
Gray K; Ficociello LH; Hunt AE; Mullon C; Brunelli SM
Int J Nephrol Renovasc Dis; 2019; 12():1-8. PubMed ID: 30774412
[TBL] [Abstract][Full Text] [Related]
11. Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
Kalantar-Zadeh K; Parameswaran V; Ficociello LH; Anderson L; Ofsthun NJ; Kwoh C; Mullon C; Kossmann RJ; Coyne DW
Am J Nephrol; 2018; 47(3):153-161. PubMed ID: 29514139
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
[TBL] [Abstract][Full Text] [Related]
13. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
14. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study.
Ferreira A; Pinto B; Navarro D; Aniceto J; Neves PL; Ponce P
J Bras Nefrol; 2019; 41(2):224-230. PubMed ID: 30742699
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
17. Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study.
Vervloet MG; Boletis IN; de Francisco ALM; Kalra PA; Ketteler M; Messa P; Stauss-Grabo M; Derlet A; Walpen S; Perrin A; Ficociello LH; Rottembourg J; Wanner C; Cannata-Andía JB; Fouque D
Clin Kidney J; 2021 Jul; 14(7):1770-1779. PubMed ID: 34221384
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.
Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
Kidney Int Rep; 2018 Jan; 3(1):185-192. PubMed ID: 29340330
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS.
Fissell RB; Karaboyas A; Bieber BA; Sen A; Li Y; Lopes AA; Akiba T; Bommer J; Ethier J; Jadoul M; Pisoni RL; Robinson BM; Tentori F
Hemodial Int; 2016 Jan; 20(1):38-49. PubMed ID: 25975222
[TBL] [Abstract][Full Text] [Related]
20. Association between phosphate binder pill burden and mortality risk in patients on maintenance hemodialysis: a single-center cohort study with 7-year follow-up of 513 patients.
Nagano N; Zushida C; Tagahara A; Miya M; Tamei N; Muto S; Tsutsui T; Ando T; Ogawa T; Ito K
Clin Exp Nephrol; 2023 Nov; 27(11):961-971. PubMed ID: 37578637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
